

NG2 and DLL3 CAR-T Cells Targeting Melanoma

NCT07193966

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Shenzhen Geno-Immune Medical Institute
Enrollment	100 participants

Plain Language Summary

This trial is testing CAR-T cell therapy — immune cells engineered to target two proteins (NG2 and DLL3) found on melanoma and other cancers — in patients whose cancer has progressed after standard first-line treatment.

****You may be eligible if...****

- You are between 18 and 75 years old
- You have a confirmed tumor that expresses NG2 and/or DLL3 proteins (tested by biopsy)
- Your cancer is non-resectable, metastatic, progressive, or recurrent
- You have already received and progressed on standard first-line treatment
- You weigh at least 40 kg and have a life expectancy of at least 8 weeks
- Any serious side effects from prior treatments have resolved to grade 2 or lower

****You may NOT be eligible if...****

- Your tumor does not express NG2 or DLL3
- You have not yet received first-line therapy
- You have recently had a stem cell or bone marrow transplant
- Your weight is below 40 kg or life expectancy is under 8 weeks

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (19)

- Patients with tumors have received standard first-line therapy and have been diagnosed with non-resectable, metastatic, progressive or recurrent conditions.
 - The expression status of NG2 and DLL3 antigens of the tumor has been determined for eligibility. Positive expression is defined by NG2 and DLL3 antibody staining results based on immunohistochemistry or flow cytometry analyses.
 - Body weight greater than or equal to 40 kg.
 - Age: ≥18 year and ≤75 years of age at the time of enrollment.
 - Life expectancy: at least 8 weeks.
- ... and 14 more (see full listing online)

Exclusion (8)

- Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction, with the exception of grade 3 hematologic toxicity.
- Untreated central nervous system (CNS) metastasis; patients with previous CNS tumor involvement that has been treated and is stable for at least 6 weeks following completion of therapy are eligible.
- Previous treatment with other genetically engineered CAR T cells.
- Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection.
- Patients who require systemic corticosteroid or other immunosuppressive therapy.

<https://clinicaltrials.gov/study/NCT07193966>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

Locations (1 total)

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China